Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239988 | 1.00 | HPGD (0.41) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL24918211 | 1.00 | HPGD (0.41) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL31239951 | 1.00 | HPGD (0.41) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL24917728 | 1.00 | HPGD (0.41) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL30752640 | 1.00 | HPGD (0.41) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL33525671 | 0.89 | HPGD (0.38) | HPGDRECQLEPHX1HSD17B10CHRM2 | |
| SCHEMBL31085641 | 0.84 | CTSK (0.43) | EPHX1HSD17B10 | |
| SCHEMBL23931038 | 0.83 | NR1H2 (0.37) | HPGDEPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL23931040 | 0.83 | NR1H2 (0.37) | HPGDEPHX1HSD17B10CHRM2CHRM1 | |
| SCHEMBL23931041 | 0.83 | NR1H2 (0.37) | HPGDEPHX1HSD17B10CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| WO-2025122619-A1 | KRAS G12C INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4565579-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | Theras, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4536668-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119630676-A | Pyrido [4,3-D ] pyrimidine derivatives as KRAS inhibitors | 百时美施贵宝公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4373822-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117916238-A | Compositions and methods for inhibiting RAS | 瑟拉斯有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| WO-2024030633-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | HPGD 1290/4885RECQL 1179/4885EPHX1 697/4885 |
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | HPGD 2289/4885RECQL 1408/4885EPHX1 2610/4885 |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | HPGD 1290/4885RECQL 1179/4885EPHX1 697/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HPGD 2494/4885RECQL 486/4885EPHX1 3386/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | HPGD 2663/4885RECQL 1877/4885EPHX1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.